Our Latest News
Find our latest news below and follow us on our social media platforms.
RxCelerate launches RxPlorer™: A new protein metastate discovery platform, unlocking new possibilities for screening against undruggable targets
RxCelerate, a leading international outsourced drug discovery and development provider, today announced the launch of RxPlorer™: a new technology for finding small molecule hits, particularly against challenging, previously undruggable targets.
RxCelerate and Constructive Bio Announce Partnership to Advance Next-Generation Therapeutics
Two Cambridge-based companies, Constructive Bio and RxCelerate, have formed a strategic partnership to develop novel biologic therapeutic candidates targeting multiple disease indications, including liver fibrosis and other cardiometabolic diseases.
RxCelerate Assembles a World-Class Scientific Advisory Board for its Biologics Discovery Unit
Cambridge, UK & Cambridge, MA, Tuesday 29 April 2025, 1pm BST RxCelerate, the Cambridge-based out-sourced drug discovery and development leader, has unveiled a world-class Scientific Advisory Board (SAB) for its rapidly growing antibody discovery group,...
RxCelerate Wins Best Performing R&D Services Provider Award
Cambridge, UK, 1st April 2025, 1pm BSTWe are delighted to share that RxCelerate was named Best Performing R&D Services Provider Company of the Year at last night’s One Nucleus Annual Awards Dinner.This award is a testament to the expertise, dedication, and...
RxCelerate & Babraham Research Campus host panel on “Prioritising mental health in the workplace”
Cambridge, UK 15th October 2024, 9AM GMTWorld Mental Health Day was on the 10th of October, and it is a day for mental health education, awareness and advocacy against social stigma. The aim of this year’s theme, “Mental Health in the Workplace”, was to highlight the...
PlaqueTec and RxCelerate collaborate on early phase drug discovery for coronary artery disease
Cambridge, UK Wednesday 18th September 2024, 9AM GMT Project evaluated small molecules against novel target in coronary artery disease discovered by PlaqueTec Bespoke cell-based assay developed by RxCelerate to test small molecules predicted to bind candidate target...